Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05827081 2026-03-02

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast

Breast Cancer Metastatic

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

333 enrolled

Breast

Breast Neoplasms, Recurrence

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

373 enrolled

Breast

Breast Neoplasms

NCT05514054 2026-01-29

EMBER-4

Phase 3 Active not recruiting

8,000 enrolled

Breast

Breast Neoplasms

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

198 enrolled

Breast

Breast Neoplasms

NCT04906395 2026-01-13

OVELIA

Phase 3 Active not recruiting

250 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Phase 3 Enrolling by invitation

250 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

779 enrolled 9 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3 Recruiting

460 enrolled

Breast

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast

Breast Neoplasms

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 2 Completed

247 enrolled 27 charts

Breast

Breast Neoplasms

NCT02123823 2025-07-15

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Phase 1 Completed

164 enrolled 21 charts

Tumor-Agnostic

Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05952557 2025-06-19

CAMBRIA-2

Phase 3 Recruiting

5,500 enrolled

Breast

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2 Active not recruiting

78 enrolled

Breast

Breast Neoplasms

Clinical Trials

OPERA-01

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

OMAHA-015

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

PIKASSO-01

PIKALO-1

Adjuvant WIDER

AMEERA-3

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

EMBER-4

Sapu003 in Advanced mTOR-sensitive Solid Tumors

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

OVELIA

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

LITESPARK-029

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

MORPHEUS HR+BC

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

EMERALD

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

EMBER-3

CAMBRIA-2

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy